Integrum AB Series B (INTEG-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integrum AB Series B (INTEG-B) has a cash flow conversion efficiency ratio of -0.099x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.51 Million ≈ $-1.67 Million USD) by net assets (Skr156.95 Million ≈ $16.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Integrum AB Series B - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Integrum AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read INTEG-B total debt and obligations for a breakdown of total debt and financial obligations.
Integrum AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integrum AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sikko Industries Limited
NSE:SIKKO
|
-0.100x |
|
UTStarcom Holdings Corp
NASDAQ:UTSI
|
-0.054x |
|
ALUMEXX N.V. NAM. EO-10
F:NE8F
|
N/A |
|
Patagonia Lithium Ltd
AU:PL3
|
-0.124x |
|
K-One Technology Bhd
KLSE:0111
|
0.102x |
|
Bluglass Ltd
AU:BLG
|
0.000x |
|
Alpha Group International plc
LSE:ALPH
|
-0.074x |
|
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
|
0.087x |
Annual Cash Flow Conversion Efficiency for Integrum AB Series B (2014–2024)
The table below shows the annual cash flow conversion efficiency of Integrum AB Series B from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Integrum AB Series B worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr177.88 Million ≈ $19.14 Million |
Skr-37.70 Million ≈ $-4.06 Million |
-0.212x | -137.47% |
| 2023-12-31 | Skr142.79 Million ≈ $15.37 Million |
Skr-12.74 Million ≈ $-1.37 Million |
-0.089x | +48.96% |
| 2022-12-31 | Skr143.53 Million ≈ $15.45 Million |
Skr-25.10 Million ≈ $-2.70 Million |
-0.175x | -37.73% |
| 2021-12-31 | Skr159.74 Million ≈ $17.19 Million |
Skr-20.28 Million ≈ $-2.18 Million |
-0.127x | +46.48% |
| 2020-12-31 | Skr24.29 Million ≈ $2.61 Million |
Skr-5.76 Million ≈ $-620.14K |
-0.237x | +69.94% |
| 2019-12-31 | Skr23.73 Million ≈ $2.55 Million |
Skr-18.72 Million ≈ $-2.01 Million |
-0.789x | +49.90% |
| 2018-12-31 | Skr16.05 Million ≈ $1.73 Million |
Skr-25.28 Million ≈ $-2.72 Million |
-1.575x | -62.44% |
| 2017-12-31 | Skr18.00 Million ≈ $1.94 Million |
Skr-17.45 Million ≈ $-1.88 Million |
-0.969x | -238.90% |
| 2016-12-31 | Skr10.53 Million ≈ $1.13 Million |
Skr-3.01 Million ≈ $-324.30K |
-0.286x | +88.15% |
| 2015-12-31 | Skr1.14 Million ≈ $122.14K |
Skr-2.74 Million ≈ $-294.76K |
-2.413x | -312.76% |
| 2014-12-31 | Skr1.13 Million ≈ $122.04K |
Skr-663.00K ≈ $-71.35K |
-0.585x | -- |
About Integrum AB Series B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more